EHA 2023 | Incidence of germline mutations in patients with myeloid neoplasms with antecedent solid tumors
Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study investigating the incidence of germline mutations in DNA mismatch repair (MMR) genes in patients with a myeloid neoplasm and antecedent solid tumors using next-generation sequencing (NGS). Dr Kanagal-Shamanna explains that germline MMR gene mutations, which can predispose a patient to solid tumors and myeloid neoplasms, were found in approximately 20% of 77 patients with myeloid neoplasms and antecedent solid tumors. These findings suggest that germline MMR mutations are not uncommon in patients with myeloid neoplasms, and that it is important for germline testing to be initiated in more cases to look for these mutations. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
